Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Mobocertinib Plus T-DM1 Elicits Preclinical Activity in HER2 Exon 20 Insertion+ Lung Cancer Models

September 13th 2021

Mobocertinib plus ado-trastuzumab emtansine demonstrated inhibitory effects in HER2 exon 20 insertion–mutated lung cancer cell lines.

ESMO Publishes Guidelines for the Management of Solid Tumor Brain Metastases

September 7th 2021

The European Association of Neuro-Oncology and ESMO have released clinical practice guidelines, which provide management recommendations for the diagnosis, treatment, and follow-up of patients with solid tumor brain metastases.

Genomic-Adjusted Radiation Dose Is Associated With First Recurrence and Survival in Solid Tumors

September 3rd 2021

Genomic-adjusted radiation dose demonstrated a significant association with time to first recurrence and overall survival in patients with certain solid tumors who had been treated with radiation therapy, indicating that genomics should be used to guide radiation dosing decisions.

Dr. Torres-Roca on Optimizing Radiation Therapy With GARD-Based Dosing in Oncology

August 30th 2021

Javier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Dr. Scott on the Incorporation of GARD-Based Radiotherapy Dosing in Oncology

August 30th 2021

Jacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

ALK Inhibitor Success Prompts Search for a Role Beyond NSCLC

August 25th 2021

The rapid development of novel agents directed at anaplastic lymphoma kinase gene fusions has emerged as one of the success stories of the targeted therapy era in non–small cell lung cancer

Dr. Scott on the Rationale to Evaluate GARD-Based Radiotherapy Dosing in Oncology

August 18th 2021

Jacob G. Scott, MD, DPhil, discusses the rationale to evaluate genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Increasing Use of Molecular Assays Will Help With Accurate NSCLC Diagnoses, Treatment Plans

August 18th 2021

Overall survival was significantly improved at 18.6 months in patients with non–small cell lung cancer who received targeted therapy compared with those who did not receive targeted therapy at 11.4 months, according to a pooled analysis of patients who received National Comprehensive Cancer Network-guided therapies in accordance with their biomarkers.

FDA Green Lights First Companion Diagnostic for Dostarlimab in dMMR Solid Tumors

August 18th 2021

The FDA has approved the VENTANA MMR RxDx panel as the first companion diagnostic test to assist in identifying patients with solid tumors that are DNA mismatch repair deficient who may be eligible to receive the anti–PD-1 therapy dostarlimab-gxly, which was recently granted an accelerated approval by the agency.

3 Precision Era Biomarkers Get a Closer Look

August 18th 2021

Circulating tumor DNA, tumor mutational burden, and homologous recombination deficiency are 3 emerging biomarkers for tailoring therapy need further clinical and technical clarity to support robust use in daily practice.

Making the Most of Molecular Testing in Breast Cancer

August 12th 2021

Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.

NTRK- and RET-Targeted Agents Reshape Solid Tumor Landscape

August 5th 2021

Understanding the oncogenic drivers behind a cancer is taking on increasing importance as more effective agents targeting specific gene aberrations continue to emerge.

CEACAM5 Joins a Growing Menu of Emerging Lung Cancer Targets

August 3rd 2021

After nearly two decades of successfully developing therapies directed at molecular aberrations in non–small cell lung cancer, investigators are exploring a new generation of novel targets, including some not specifically associated with driver mutations.

Dr. Puri on the Rationale to Evaluate Real-World Multiomic Characterization of SCLC Subtypes

August 2nd 2021

Sonam Puri, MD, discusses the rationale to evaluate the real-world multiomic characterization of small cell lung cancer subtypes.

Dr. Mamdani on Evaluating the Immunogenicity of STK11/TP53 Co-Mutations in NSCLC

August 2nd 2021

Hirva Mamdani, MD, discusses the rationale to evaluate the immunogenicity of STK11 and TP53 co-mutations in non–small cell lung cancer.

Dr. Naqash on the Results of a Tumor Profiling Study in STK11/TP53 Co-Mutated NSCLC

August 2nd 2021

Abdul Rafeh Naqash, MD, discusses the results of a tumor profiling study in STK11 and TP53 co-mutated non–small cell lung cancer.

4 Novel Drug Classes Demonstrate Early Promise for EGFR-Mutated NSCLC

July 31st 2021

Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.

Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC

July 31st 2021

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

Bispecifics Prove to Have Intriguing Role in Lung Cancer

July 30th 2021

Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.

Understanding Actionable Pathogenic Variants Among Caribbean Patients With Breast and Ovarian Cancers

July 29th 2021

Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of hereditary breast and ovarian cancers in populations throughout the Caribbean.